I
Ian Kennedy
Researcher at Waikato Hospital
Publications - 12
Citations - 1905
Ian Kennedy is an academic researcher from Waikato Hospital. The author has contributed to research in topics: Cancer & Metastatic breast cancer. The author has an hindex of 6, co-authored 11 publications receiving 1861 citations. Previous affiliations of Ian Kennedy include Royal Prince Alfred Hospital & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
Gabriel N. Hortobagyi,R. L. Theriault,Lester Porter,Douglas W. Blayney,Allan Lipton,Clive Sinoff,Helen Wheeler,Joseph F. Simeone,John J. Seaman,Robert Knight,Maika Heffernan,Dirk J. Reitsma,Ian Kennedy,Simon G. Allan,Kathleen Mellars +14 more
TL;DR: In this paper, pamidronate disodium (90 mg) was given to women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion.
Journal ArticleDOI
Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial
Richard L. Theriault,Allan Lipton,Gabriel N. Hortobagyi,Richard Leff,Stefan Glück,John F. Stewart,Sean Costello,Ian Kennedy,Joseph F. Simeone,John J. Seaman,Robert Knight,Kathleen Mellars,Maika Heffernan,Dirk J. Reitsma +13 more
TL;DR: In this paper, the authors evaluated whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy.
Journal ArticleDOI
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
James F. Bishop,J. Dewar,G. C. Toner,Jennifer A. Smith,Martin H.N. Tattersall,Ian N. Olver,Stephen P. Ackland,Ian Kennedy,David Goldstein,Howard Gurney,Euan Walpole,John A. Levi,Jennifer Stephenson,Renzo M. Canetta +13 more
TL;DR: Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
Journal Article
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
James F. Bishop,J. Dewar,G. C. Toner,Martin H.N. Tattersall,Ian N. Olver,Stephen P. Ackland,Ian Kennedy,David Goldstein,Howard Gurney,Euan Walpole,John A. Levi,Joe Stephenson +11 more
TL;DR: Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides comparable control of metastatic cancer to CMFP combination therapy when used as front-line treatment.
Journal Article
Paclitaxel as First-Line Treatment for Metastatic Breast Cancer
James F. Bishop,J. Dewar,Guy C. Toner,Martin H.N. Tattersall,Ian N. Olver,Stephen P. Ackland,Ian Kennedy,David Goldstein,Howard Gurney,Euan Walpole,John A. Levi,Jennifer Stephenson +11 more
TL;DR: In this paper, a trial was undertaken to compare paclitaxel (Taxol) with standard in pretreated patients with advanced breast cancer, and the results showed that Taxol exhibits remarkable antitumor activity.